Grufity logo
Grufity logo
EWTX

EWTX - Edgewise Therapeutics, Inc. Stock Price, Fair Value and News

$40.39+0.04 (+0.10%)
Delayed as of 29 Jul 2026, 10:02 am ET

12/100

EWTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

12/100

EWTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EWTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EWTX Price Action

Last 7 days

1.8%

Last 30 days

-2.8%

Last 90 days

32.4%

Trailing 12 Months

182.7%

EWTX RSI Chart

EWTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EWTX Valuation

Market Cap

4.3B

Price/Earnings (Trailing)

-24.67

Price/Sales (Trailing)

184.33

EV/EBITDA

-25.62

Price/Free Cashflow

-28.77

EWTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EWTX Fundamentals

EWTX Revenue

Revenue (TTM)

23.6M

Rev. Growth (Yr)

-1.14%

Rev. Growth (Qtr)

-11.47%

EWTX Earnings

Earnings (TTM)

-176.0M

Earnings Growth (Yr)

-20.14%

Earnings Growth (Qtr)

2.4%

EWTX Profitability

EBT Margin

-712.47%

Return on Equity

-35.69%

Return on Assets

-33.94%

Free Cashflow Yield

-3.48%

EWTX Investor Care

Shares Dilution (1Y)

13.10%

EWTX Alerts

  • 1 major insider sales recently.
Revenue & Growth

How Edgewise Therapeutics, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202623.6M---
202524.0M23.8M23.7M23.6M
202417.6M20.3M22.9M25.0M
20236.7M10.2M13.1M14.2M
2022526.0K843.0K1.5M4.0M
202148.0K152.0K278.0K402.0K
2020---69.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Edgewise Therapeutics, Inc.

EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.
 CEO
 WEBSITEedgewisetx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES74

Edgewise Therapeutics, Inc. Frequently Asked Questions

EWTX is the stock ticker symbol of Edgewise Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jul 28 2026, market cap of Edgewise Therapeutics, Inc. is 4.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Jul 28 2026, EWTX's PE ratio (Price to Earnings) is -24.67 and Price to Sales (PS) ratio is 184.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EWTX PE ratio will change depending on the future growth rate expectations of investors.